John M Kane

Summary

Affiliation: Long Island Jewish Medical Center
Country: USA

Publications

  1. ncbi Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications
    David Straker
    Department of Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY, USA
    Am J Psychiatry 162:1217-21. 2005
  2. pmc Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
    Stephen J Ruberg
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Psychiatry 11:23. 2011
  3. pmc Cost of antipsychotic polypharmacy in the treatment of schizophrenia
    Baojin Zhu
    Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 8:19. 2008
  4. doi Clinical guideline recommendations for antipsychotic long-acting injections
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, 75 59 263 Street, Glen Oaks, NY 11004, USA
    Br J Psychiatry Suppl 52:S63-7. 2009
  5. doi A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004 1150, USA
    J Clin Psychiatry 70:1348-57. 2009
  6. ncbi Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials
    John M Kane
    The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Psychopharmacol 24:1019-29. 2010
  7. doi Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Albert Einstein College of Medicine, 75 59 263rd St, Glen Oaks, NY 11004, USA
    Am J Psychiatry 167:181-9. 2010
  8. ncbi PORT recommendations
    John M Kane
    Psychiatric Research, Long Island Jewish Hillside Medical Center, 75 59 263rd St, Glen Oaks, NY 11004, USA
    Schizophr Bull 30:605-7. 2004
  9. ncbi Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine
    John M Kane
    Zucker Hillside Hospital and The Albert Einstein College of Medicine, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 68:213-23. 2007
  10. ncbi Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Clin Psychopharmacol 30:106-15. 2010

Collaborators

Detail Information

Publications120 found, 100 shown here

  1. ncbi Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications
    David Straker
    Department of Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY, USA
    Am J Psychiatry 162:1217-21. 2005
    ..The authors' goal was to explore the relationship between second-generation antipsychotics and the metabolic syndrome...
  2. pmc Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
    Stephen J Ruberg
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Psychiatry 11:23. 2011
    ..To identify a simple decision tree using early symptom change to predict response to atypical antipsychotic therapy in patients with (Diagnostic and Statistical Manual, Fourth Edition, Text Revised) chronic schizophrenia...
  3. pmc Cost of antipsychotic polypharmacy in the treatment of schizophrenia
    Baojin Zhu
    Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 8:19. 2008
    ..This study compared the costs of antipsychotic polypharmacy for patients who initiated on 1 of the 3 most commonly prescribed atypical antipsychotics - olanzapine, quetiapine, or risperidone...
  4. doi Clinical guideline recommendations for antipsychotic long-acting injections
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, 75 59 263 Street, Glen Oaks, NY 11004, USA
    Br J Psychiatry Suppl 52:S63-7. 2009
    ..Long-acting injections (LAIs) of antipsychotic drugs were developed over 40 years ago in an attempt to improve the long-term treatment of schizophrenia...
  5. doi A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004 1150, USA
    J Clin Psychiatry 70:1348-57. 2009
    ..Combining antipsychotics is common practice in the treatment of schizophrenia. This study investigated aripiprazole adjunctive to risperidone or quetiapine for treating schizophrenia and schizoaffective disorder...
  6. ncbi Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials
    John M Kane
    The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Psychopharmacol 24:1019-29. 2010
    ..In conclusion, akathisia with aripiprazole occurred early in treatment, was mild-to-moderate in severity, led to few study discontinuations, and did not compromise therapeutic efficacy...
  7. doi Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Albert Einstein College of Medicine, 75 59 263rd St, Glen Oaks, NY 11004, USA
    Am J Psychiatry 167:181-9. 2010
    ..The purpose of the present study was to evaluate the efficacy and tolerability of olanzapine long-acting injection for maintenance treatment of schizophrenia...
  8. ncbi PORT recommendations
    John M Kane
    Psychiatric Research, Long Island Jewish Hillside Medical Center, 75 59 263rd St, Glen Oaks, NY 11004, USA
    Schizophr Bull 30:605-7. 2004
  9. ncbi Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine
    John M Kane
    Zucker Hillside Hospital and The Albert Einstein College of Medicine, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 68:213-23. 2007
    ..Treatment-resistant schizophrenia poses a major therapeutic challenge. This multicenter, double-blind, randomized study compared the efficacy and safety of aripiprazole and perphenazine in treatment-resistant patients with schizophrenia...
  10. ncbi Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Clin Psychopharmacol 30:106-15. 2010
    ..Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms...
  11. doi Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Clin Psychopharmacol 28:S29-35. 2008
    ..4 msec (haloperidol) at end point. Iloperidone demonstrated long-term efficacy equivalent to haloperidol and a favorable long-term safety profile, potentially making this agent a suitable option as maintenance therapy for schizophrenia...
  12. doi Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, New York 11004, USA
    Appl Health Econ Health Policy 7:109-19. 2009
    ..Since their introduction, second-generation antipsychotics (SGAs) have become the drugs of choice for the treatment of schizophrenia. However, recent findings have questioned the benefits of SGAs over first-generation antipsychotics (FGAs)...
  13. ncbi Creating a health care team to manage chronic medical illnesses in patients with severe mental illness: the public policy perspective
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, 75 59 263rd St, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 70:37-42. 2009
    ..Mental health providers should help improve the integration of primary care and mental health care and implement treatment strategies for changing modifiable health risk factors in their patients with severe mental illness...
  14. ncbi Review of treatments that can ameliorate nonadherence in patients with schizophrenia
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, 75 59 263rd Street, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 67:9-14. 2006
    ....
  15. doi A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, 75 59 263rd St, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 72:194-204. 2011
    ..The objective of this study was to examine the efficacy and safety of sertindole, compared to risperidone, in this patient population...
  16. doi The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, New York, NY, USA
    Schizophr Res 105:208-15. 2008
    ..To examine the efficacy of aripiprazole across symptoms in patients with acute exacerbation of schizophrenia or schizoaffective disorder...
  17. ncbi A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004 1150, USA
    J Clin Psychiatry 70:572-81. 2009
    ..To evaluate the effectiveness of olanzapine versus aripiprazole in patients with schizophrenia...
  18. ncbi An evidence-based strategy for remission in schizophrenia
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 69:25-30. 2008
    ..This article briefly reviews the status of remission as a therapeutic goal in the treatment of schizophrenia and summarizes available treatment research reporting remission and recovery as clinical outcomes...
  19. ncbi Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia
    John M Kane
    The Zucker Hillside Hospital and The Albert Einstein College of Medicine, Glen Oaks, New York, USA
    Int Clin Psychopharmacol 21:21-8. 2006
    ..Ziprasidone was associated with a greater decrease in median prolactin levels and a lower incidence of clinically significant weight change. Neither agent caused any clinically important changes in QTc interval...
  20. pmc Commentary: consensus statement on negative symptoms
    John Kane
    Schizophr Bull 32:223-4. 2006
  21. ncbi Akathisia: an updated review focusing on second-generation antipsychotics
    John M Kane
    The Zucker Hillside Hospital, Department of Psychiatry, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 70:627-43. 2009
    ..Also, to provide a review of the literature on the incidence of drug-induced akathisia associated with the use of second-generation antipsychotics (SGAs) and first-generation antipsychotics (FGAs)...
  22. ncbi Atypical antipsychotics: sedation versus efficacy
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 69:18-31. 2008
    ....
  23. doi Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004 1150, USA
    J Clin Psychiatry 71:1475-81. 2010
    ..To evaluate the efficacy and tolerability of armodafinil, the longer-lasting isomer of modafinil, as adjunctive therapy in patients with schizophrenia...
  24. pmc Past and present progress in the pharmacologic treatment of schizophrenia
    John M Kane
    Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 71:1115-24. 2010
    ....
  25. pmc Unanswered questions in schizophrenia clinical trials
    John M Kane
    The Zucker Hillside Hospital, Glen Oaks, New York, NY, USA
    Schizophr Bull 34:302-9. 2008
  26. pmc Issues in psychopharmacology
    John M Kane
    The Zucker Hillside Hospital Glen Oaks, New York, NY, USA
    Schizophr Bull 34:258. 2008
  27. doi A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, 75 59 263rd St, Kaufmann Bldg, Ste 103, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 72:349-55. 2011
    ..Long-term efficacy of asenapine in preventing schizophrenia relapse was assessed in a 26-week double-blind, placebo-controlled trial that followed 26 weeks of open-label treatment...
  28. ncbi Progress defined--short-term efficacy, long-term effectiveness
    J Kane
    Department of Psychiatry, Long Island Jewish Medical Center, New York, USA
    Int Clin Psychopharmacol 16:S1-8. 2001
    ..These drugs may, therefore, provide clinicians with a new and important addition for first-line management of schizophrenia...
  29. doi Strategies for making an accurate differential diagnosis of schizoaffective disorder
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, New York, USA
    J Clin Psychiatry 71:4-7. 2010
    ..Careful documentation of symptoms and recording of the basis for diagnosis are crucial so that the diagnosis can be reevaluated over time...
  30. ncbi Treatment strategies to prevent relapse and encourage remission
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 68:27-30. 2007
    ..Therefore, achieving the goals of remission and recovery is in the best interest not only of patients with schizophrenia but also of society...
  31. ncbi Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital of the North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 64:3-5. 2003
  32. ncbi Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital of the North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 64:19-25. 2003
    ..Available clinical data support rapid titration to > or = 120 mg/day for optimal efficacy in patients with acute exacerbation of schizophrenia...
  33. ncbi Treatment models and designs for intervention research during the psychotic prodrome
    John M Kane
    The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Schizophr Bull 29:747-56. 2003
    ..Finally, the methodology of completed and ongoing intervention trials in putative prodromal populations is discussed...
  34. pmc Pharmacologic treatment of schizophrenia
    John M Kane
    Zucker Hillside Hospital, 75 59 263rd Street, Glen Oaks, NY 11004, USA
    Dialogues Clin Neurosci 12:345-57. 2010
    ..Moreover, new treatment options are needed that affect nondopaminergic targets with relevance for symptom reduction, relapse prevention, enhanced efficacy for nonresponders, and reduced key adverse effects...
  35. ncbi Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 65:16-20. 2004
    ..This article will review studies of the prevalence and incidence of tardive dyskinesia in patients taking antipsychotic agents...
  36. ncbi Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Terry E Goldberg
    Zucker Hillside Hospital, 7559 263rd Street, Glen Oaks, NY 11004, USA
    Arch Gen Psychiatry 64:1115-22. 2007
    ..However, none of these studies included healthy controls undergoing repeated testing to assess the possibility that improvements might reflect simple practice effects...
  37. pmc DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia
    Philip R Szeszko
    Feinstein Institute for Medical Research, Manhasset, NY, USA
    Biol Psychol 79:103-10. 2008
    ..Given that DISC1 plays a role in cerebral cortex development, polymorphisms in this gene may have relevance for neurobiological models of schizophrenia that have implicated cortical deficits in its pathophysiology...
  38. pmc Patterns of stress in schizophrenia
    Julia D Betensky
    Department of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Psychiatry Res 160:38-46. 2008
    ....
  39. ncbi Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain
    Anil K Malhotra
    Psychiatry Research, Zucker Hillside Hospital, 75 59 263rd St, Glen Oaks, NY 11004, USA
    Arch Gen Psychiatry 69:904-12. 2012
    ..Unfortunately, SGAs are often associated with substantial weight gain, with no means to predict which patients are at greatest risk...
  40. ncbi Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
    John M Kane
    Zucker Hillside Hospital, Glen Oaks, NY, USA
    J Clin Psychiatry 63:763-71. 2002
    ..Aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile. The present study investigated the efficacy, safety, and tolerability of aripiprazole and haloperidol compared with placebo...
  41. ncbi Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks
    John M Kane
    The Zucker Hillside Hospital, 75 59 263 St, Glen Oaks, NY 11004, USA
    Schizophr Res 95:143-50. 2007
    ..This analysis examined symptomatic remission in acutely ill patients with schizophrenia receiving either aripiprazole or haloperidol for one year...
  42. pmc The genetics of symptom-based phenotypes: toward a molecular classification of schizophrenia
    Pamela DeRosse
    Center for Translational Psychiatry, The Feinstein Institute for Medical Research, Manhasset, NY, USA
    Schizophr Bull 34:1047-53. 2008
    ..We examined these chromosomal regions for association to positive, negative, and disorganized symptom clusters, using a dense set of single-nucleotide polymorphisms (SNPs)...
  43. pmc Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
    Christoph U Correll
    The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, United States
    Schizophr Res 89:91-100. 2007
    ..To determine whether the coprescribing of two or more antipsychotics, a relatively frequent practice with little data to support its safety and efficacy, is associated with an increased prevalence of metabolic syndrome...
  44. pmc Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia
    Christoph U Correll
    The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, New York 11004, USA
    J Child Adolesc Psychopharmacol 18:475-90. 2008
    ....
  45. ncbi Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia
    Philip R Szeszko
    Department of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Neuropsychopharmacology 33:976-84. 2008
    ..These abnormalities have clinical and neuropsychological correlates, which may be useful in further characterizing structure-function relations in schizophrenia and constraining neurobiological models of the disorder...
  46. pmc Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome
    Christoph U Correll
    Albert Einstein College of Medicine, Department of Psychiatry, Bronx, NY, USA
    Schizophr Bull 33:703-14. 2007
    ..The presence and specificity of a bipolar prodrome remains questioned. We aimed to characterize the prodrome prior to a first psychotic and nonpsychotic mania and to examine the phenotypic proximity to the schizophrenia prodrome...
  47. pmc Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability
    Katherine E Burdick
    Hillside Hospital, North Shore Long Island Jewish Health System, Department of Psychiatry Research, Glen Oaks, NY 11004, USA
    Am J Psychiatry 167:436-43. 2010
    ..Thus, MET may be of particular interest as a candidate gene for neuropsychiatric diseases with a developmental etiology, including schizophrenia...
  48. ncbi Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia
    Pamela DeRosse
    Department of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, New York 11004, USA
    Biol Psychiatry 61:1208-10. 2007
    ....
  49. ncbi White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study
    Philip R Szeszko
    The Zucker Hillside Hospital, Department of Psychiatry Research, 75 59 263rd St, Glen Oaks, NY 11004, USA
    Am J Psychiatry 162:602-5. 2005
    ..The goal of this study was to investigate brain white matter abnormalities by using diffusion tensor imaging in patients with schizophrenia or schizoaffective disorder close to illness onset...
  50. pmc Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia
    Philip R Szeszko
    Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA
    Schizophr Bull 38:569-78. 2012
    ....
  51. pmc Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?
    Juan A Gallego
    The Zucker Hillside Hospital, NY 11004, USA
    J Clin Psychiatry 72:1691-6. 2011
    ..This analysis explored trial duration with first-episode patients and asked whether early limited improvement predicts ultimate lack of treatment response with first-episode patients as it does with multiepisode patients...
  52. pmc Obesity and coronary risk in patients treated with second-generation antipsychotics
    Christoph U Correll
    The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, 75 59 263rd Street, Glen Oaks, NY, 11004, USA
    Eur Arch Psychiatry Clin Neurosci 261:417-23. 2011
    ..Obesity does not appear to be an independent predictor for the 10-year risk of coronary heart disease events in patients without metabolic syndrome treated with second-generation antipsychotics...
  53. ncbi DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients
    Todd Lencz
    Department of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    Am J Psychiatry 163:529-31. 2006
    ....
  54. pmc DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia
    Todd Lencz
    Division of Psychiatry Research, The Zucker Hillside Hospital, 75 59 263rd Street, Glen Oaks, NY 11004, USA
    Pharmacogenet Genomics 20:569-72. 2010
    ..Given earlier evidence that deletion carriers show reduced symptom response to medication, additional study of appropriate treatment options for these patients seems warranted...
  55. ncbi Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity?
    Anil K Malhotra
    Division of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, and Albert Einstein College of Medicine, United States
    Schizophr Res 87:181-4. 2006
    ..We tested the hypothesis that ziprasidone improves cognition in the absence of clinical improvement...
  56. ncbi Dysbindin genotype and negative symptoms in schizophrenia
    Pamela DeRosse
    Department of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Am J Psychiatry 163:532-4. 2006
    ....
  57. pmc Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents
    Christoph U Correll
    Zucker Hillside Hospital, Psychiatry Research, North Shore Long Island Jewish Health System, 75 59 263rd St, Glen Oaks, NY 11004, USA
    JAMA 302:1765-73. 2009
    ..Cardiometabolic effects of second-generation antipsychotic medications are concerning but have not been sufficiently studied in pediatric and adolescent patients naive to antipsychotic medication...
  58. doi Medical outcome of patients with dementia in a free-standing psychiatric hospital
    Peter Manu
    The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    J Geriatr Psychiatry Neurol 26:29-33. 2013
    ..The hospital outcome of patients with dementia is significantly worse than that of cognitively intact persons of the same age admitted to medical or surgical units but has not been investigated in psychiatric settings...
  59. pmc Quantifying clinical relevance in the treatment of schizophrenia
    Christoph U Correll
    Zucker Hillside Hospital, Psychiatry Research, North Shore Long Island Jewish Health System, Glen Oaks, New York, USA
    Clin Ther 33:B16-39. 2011
    ..While in research studies, the use of quantitative assessments is ubiquitous, this is not the case in routine clinical practice, creating an important translational practice gap...
  60. pmc Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control study
    Christoph U Correll
    North Shore Long Island Jewish Health System, The Zucker Hillside Hospital, Glen Oaks, New York 11004, USA
    J Child Adolesc Psychopharmacol 21:365-8. 2011
    ..The rate-corrected QT interval (QTc) prolongation is a risk factor for sudden cardiac death and may be induced by antipsychotic drugs...
  61. ncbi Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes
    Delbert G Robinson
    Department of Psychiatry, The Zucker Hillside Hospital of the North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Am J Psychiatry 163:2096-102. 2006
    ..The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders...
  62. ncbi Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies
    Christoph U Correll
    Department of Psychiatry Research, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Schneider Children s Hospital, Glen Oaks, NY 11004, USA
    Am J Psychiatry 161:414-25. 2004
    ..This hypothesis was examined in a systematic review of studies involving open or controlled treatment with any second-generation antipsychotic...
  63. ncbi The effects of clozapine and risperidone on spatial working memory in schizophrenia
    Susan R McGurk
    Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Pl, New York, NY 10029, USA
    Am J Psychiatry 162:1013-6. 2005
    ..The purpose of this investigation was to evaluate the effects of clozapine and risperidone on spatial working memory in patients with schizophrenia...
  64. pmc Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia
    Todd Lencz
    Department of Psychiatry Research, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, 75 59 263rd Street, Glen Oaks, NY 11004, USA
    Proc Natl Acad Sci U S A 104:19942-7. 2007
    ..Other risk ROHs feature haplotypes that are also common in healthy individuals, possibly indicating a source of balancing selection...
  65. doi Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, 75 59 263rd Street, Kaufmann Bldg, Suite 103, Glen Oaks, NY 11004 1150, USA
    Schizophr Res 135:116-22. 2012
    ..This study investigated the efficacy and tolerability of adjunctive armodafinil for treatment of negative symptoms in adults with schizophrenia receiving antipsychotic medications...
  66. ncbi White matter abnormalities in early-onset schizophrenia: a voxel-based diffusion tensor imaging study
    Sanjiv Kumra
    Department of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    J Am Acad Child Adolesc Psychiatry 44:934-41. 2005
    ..To investigate abnormalities in the structural integrity of brain white matter as suggested by diffusion tensor imaging in adolescents with early-onset schizophrenia (onset of psychosis by age 18)...
  67. ncbi COMT genotype and manic symptoms in schizophrenia
    Pamela DeRosse
    Department of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, 75 59 263rd Street, Glen Oaks, NY 11004, and Harvard Partners Center for Genetics and Genomics, Boston, MA, United States
    Schizophr Res 87:28-31. 2006
    ..These data suggest that the effect of COMT variation may be associated with comorbid manic symptoms in SZ...
  68. pmc Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes
    Todd Lencz
    The Zucker Hillside Hospital, Psychiatry Research, 75 59 263rd Street, Glen Oaks, New York 11004, USA
    Br J Psychiatry 194:313-8. 2009
    ..Brain-derived neurotrophic factor variants may help clarify the status of schizoaffective disorder...
  69. ncbi Clinical insights into pharmacogenetics and schizophrenia, part 2
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, USA
    J Clin Psychiatry 69:1006-13. 2008
  70. ncbi Smaller anterior hippocampal formation volume in antipsychotic-naive patients with first-episode schizophrenia
    Philip R Szeszko
    Department of Psychiatry Research, The Zucker Hillside Hospital, 75 59 263rd St, Glen Oaks, NY 11004, USA
    Am J Psychiatry 160:2190-7. 2003
    ..The authors investigated volumetric alterations of the anterior hippocampal formation in patients experiencing a first episode of schizophrenia relative to healthy comparison subjects...
  71. ncbi Early identification and high-risk strategies for bipolar disorder
    Christoph U Correll
    The Zucker Hillside Hospital, Psychiatry Research, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Bipolar Disord 9:324-38. 2007
    ..To describe and compare the relative merits of different identification strategies for individuals at risk for bipolar disorder (BPD)...
  72. ncbi Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic
    John M Kane
    The Zucker Hillside Hospital, New York, NY 11004, USA
    Am J Psychiatry 160:1125-32. 2003
    ..The authors assessed the efficacy and safety of the first long-acting atypical antipsychotic (long-acting injectable risperidone) in patients with schizophrenia...
  73. ncbi Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs
    Christoph U Correll
    The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 67:575-83. 2006
    ....
  74. ncbi Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, 260 Stetson St, Suite 3224, Cincinnati, OH 45267 0559, USA
    J Clin Psychiatry 70:4-46. 2009
    ..Summit faculty member opinion is compared with field survey results, and recommendations are made for future research...
  75. ncbi Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies
    John M Kane
    Albert Einstein College of Medicine, Bronx, NY, USA
    J Clin Psychiatry 64:34-40. 2003
    ....
  76. ncbi Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data
    Roy H Perlis
    Department of Psychiatry, Massachusetts General Hospital, 50 Staniford Street, Boston, MA 02114, USA
    Am J Psychiatry 159:1155-9. 2002
    ..To assess the effect of abrupt change in lithium dose, the authors reanalyzed data from a previously reported, randomized, double-blind trial of standard- versus low-dose lithium for maintenance therapy in bipolar disorder...
  77. ncbi Metabolic effects of treatment with atypical antipsychotics
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA
    J Clin Psychiatry 65:1447-55. 2004
  78. ncbi Remission in schizophrenia: proposed criteria and rationale for consensus
    Nancy C Andreasen
    Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA
    Am J Psychiatry 162:441-9. 2005
    ..These criteria should facilitate research and support a positive, longer-term approach to studying outcome in patients with schizophrenia...
  79. ncbi Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, USA
    J Clin Psychiatry 67:831-2. 2006
  80. ncbi Treatment adherence and long-term outcomes
    John M Kane
    Behavioral Health Services, North Shore Long Island Jewish Health System, NY, USA
    CNS Spectr 12:21-6. 2007
    ..A number of strategies have been developed to assess and facilitate adherence. The first critical step is clinician awareness of the scope of the problem and consideration of appropriate strategies to address it...
  81. ncbi Reduced frontal white matter integrity in early-onset schizophrenia: a preliminary study
    Sanjiv Kumra
    Department of Research, Zucker Hillside Hospital, Glen Oaks, New York 11004, USA
    Biol Psychiatry 55:1138-45. 2004
    ..Diffusion tensor imaging provides a relatively new approach for quantifying possible connectivity of WM in vivo...
  82. ncbi Utilization of long-acting antipsychotic medication in patient care
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, New York, NY, USA
    CNS Spectr 11:1-7; quiz 7-8. 2006
    ..Injectables and long-acting formulations of antipsychotics offer additional benefits in terms of ensuring treatment adherence...
  83. ncbi Relapse prevention in patients with schizophrenia
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA
    J Clin Psychiatry 69:e11. 2008
    ..To help the patient achieve treatment goals, intervention strategies such as switching medications and implementing psychosocial therapies are considered...
  84. pmc Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials
    Christoph U Correll
    The Zucker Hillside Hospital, Psychiatry Research, Glen Oaks, New York, NY 11004, USA
    Schizophr Bull 35:443-57. 2009
    ..Despite lacking evidence for its safety and efficacy, antipsychotic cotreatment is common in schizophrenia. Objective: To evaluate therapeutic and adverse effects of antipsychotic cotreatment vs monotherapy in schizophrenia...
  85. ncbi Sex differences in frontal lobe white matter microstructure: a DTI study
    Philip R Szeszko
    Department of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, 75 59 263rd Street, Glen Oaks, NY 11004, USA
    Neuroreport 14:2469-73. 2003
    ..Our findings may be indicative of increased directional coherence and/or density of left hemisphere white matter fibers and a leftward asymmetry of this structural integrity among women compared to men...
  86. ncbi Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects
    Gwenn S Smith
    Department of Psychiatry Research, Hillside Hospital, Neuroscience Institute of the North Shore Long Island Jewish Health System, Glen Oaks, New York 11004, USA
    Synapse 45:105-12. 2002
    ..Future studies will evaluate how the acute metabolic response to citalopram relates to the metabolic response after chronic treatment in patients with geriatric depression...
  87. ncbi Genomics and the future of pharmacotherapy in psychiatry
    Anil K Malhotra
    Division of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    Int Rev Psychiatry 19:523-30. 2007
    ..These increasingly comprehensive approaches should provide informative data on the genes associated with psychotropic drug response, a critical step towards the ultimate goal of 'personalized' medicine...
  88. ncbi Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia
    Philip R Szeszko
    Zucker Hillside Hospital, Psychiatry Research, 75 59 263rd Street, Glen Oaks, NY 11004, USA
    Br J Psychiatry 190:230-6. 2007
    ..Despite the high prevalence of cannabis use in schizophrenia, few studies have examined the potential relationship between cannabis exposure and brain structural abnormalities in schizophrenia...
  89. ncbi Early prediction of antipsychotic response in schizophrenia
    Christoph U Correll
    Department of Psychiatry Research, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Am J Psychiatry 160:2063-5. 2003
    ..The authors' goal was to examine the predictive value of early symptom changes indicating response to antipsychotic medication in schizophrenia...
  90. pmc Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study
    Sanjiv Kumra
    Department of Child and Adolescent Psychiatry, University of Minnesota, Minneapolis, Minnesota 55454 1495, USA
    J Child Adolesc Psychopharmacol 18:307-16. 2008
    ....
  91. ncbi Physical health monitoring of patients with schizophrenia
    Stephen R Marder
    Department of Veterans Affairs Greater Los Angeles Healthcare System, CA, USA
    Am J Psychiatry 161:1334-49. 2004
    ..The authors discuss a consensus panel's recommendations for improving the physical health monitoring of patients with schizophrenia who are treated in outpatient settings...
  92. ncbi Chronic restlessness with antipsychotics
    Irene M Bratti
    San Diego VA Mental Illness Research, Education, and Clinical Center, CA, USA
    Am J Psychiatry 164:1648-54. 2007
  93. ncbi Do clozapine and risperidone affect social competence and problem solving?
    Alan S Bellack
    Mental Health Research, Education and Clinical Center, VA Maryland Health Care System, Baltimore 21201, USA
    Am J Psychiatry 161:364-7. 2004
    ..The purpose of this investigation was to evaluate the effects of clozapine and risperidone on social skill and problem solving in patients with schizophrenia...
  94. ncbi Clinical guidelines: Dosing and switching strategies for long-acting risperidone
    Stephen R Marder
    VA Greater Los Angeles Health Care System, West Los Angeles Health Center, and the Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, USA
    J Clin Psychiatry 64:41-6. 2003
  95. ncbi Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Schizophr Res 102:230-40. 2008
    ..To test whether early onset of response to antipsychotic medications accurately predicts subsequent response in the treatment of patients with schizophrenia...
  96. ncbi Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders
    Lars Helldin
    The NU Health Care, Department of Psychiatry, SE 461 85 Trollhättan, Sweden
    Schizophr Res 93:160-8. 2007
    ..The hypothesis was that patients having attained remission would function at a higher level and have a lower care requirement than those who had not attained remission...
  97. ncbi The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics
    Brian L Strom
    Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
    J Clin Psychiatry 69:114-21. 2008
    ..Ziprasidone has been used to treat schizophrenia since 2000. It is unknown whether its modest QTc-prolonging effect increases cardiovascular event risk...
  98. doi Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study
    Stefan Leucht
    Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaningerstr 22, 81675 Munchen, Germany
    Schizophr Res 101:312-9. 2008
    ..To use the degree of response after 2 weeks of treatment to predict non-response at 4 to 6 weeks...
  99. ncbi An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine
    Christopher D Carlson
    Eli Lilly and Company, Indianapolis, Ind, USA
    J Clin Psychiatry 64:898-906. 2003
    ....
  100. ncbi Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials
    Stefan Leucht
    Klinik and Poliklinik für Psychiatrie und Psychotherapie der Technichen Universität München, Germany
    Am J Psychiatry 160:1209-22. 2003
    ..The authors performed a systematic review and meta-analysis of studies of the potential of new-generation antipsychotic drugs to improve adherence and decrease relapse rates in patients with schizophrenia...

Research Grants23

  1. Treating Refractory Childhood Schizophrenia
    John Kane; Fiscal Year: 2001
    ....
  2. PROSPECTIVE STUDY OF TARDIVE DYSKINESIA DEVELOPMENT
    John Kane; Fiscal Year: 2001
    ..This strategy will provide a rapid and cost-effective answer to a critical question. ..
  3. PREVENTING MORBIDITY IN FIRST EPISODE SCHIZOPHRENIA
    John Kane; Fiscal Year: 2001
    ..The results will provide a basis for informed treatment choices for clinicians as well as address the crucial question of the potential of the new treatments to improve the longitudinal course of this devastating illness. ..
  4. Treating Refractory Childhood Schizophrenia
    John Kane; Fiscal Year: 2002
    ....
  5. Treating Refractory Childhood Schizophrenia
    John Kane; Fiscal Year: 2003
    ....
  6. Treating Refractory Childhood Schizophrenia
    John Kane; Fiscal Year: 2004
    ....
  7. Relapse Prevention Study: Steering and Implementation
    John Kane; Fiscal Year: 2007
    ..The study addresses questions that are unlikely to be studied by pharmaceutical industry sponsors and will generate unique information regarding long-term treatment options for schizophrenia. ..
  8. PREVENTING MORBIDITY IN FIRST EPISODE SCHIZOPHRENIA
    John Kane; Fiscal Year: 2000
    ..The results will provide a basis for informed treatment choices for clinicians as well as address the crucial question of the potential of the new treatments to improve the longitudinal course of this devastating illness. ..
  9. PROSPECTIVE STUDY OF TARDIVE DYSKINESIA DEVELOPMENT
    John Kane; Fiscal Year: 2000
    ..This strategy will provide a rapid and cost-effective answer to a critical question. ..
  10. PROSPECTIVE STUDY OF TARDIVE DYSKINESIA DEVELOPMENT
    John Kane; Fiscal Year: 1999
    ..This strategy will provide a rapid and cost-effective answer to a critical question. ..
  11. PREVENTING MORBIDITY IN FIRST EPISODE SCHIZOPHRENIA
    John Kane; Fiscal Year: 1999
    ..The results will provide a basis for informed treatment choices for clinicians as well as address the crucial question of the potential of the new treatments to improve the longitudinal course of this devastating illness. ..